|本期目录/Table of Contents|

[1]李世崇,叶玲玲,刘红,等.重组人尿激酶原在CHO细胞中的高效表达及其纯化[J].生物加工过程,2012,10(05):50-54.[doi:10.3969/j.issn.1672-3678.2012.05.010]
 LI Shichong,YE Lingling,LIU Hong,et al.Efficient expression of recombinant human pro-urokinase in CHO cells and its purification[J].Chinese Journal of Bioprocess Engineering,2012,10(05):50-54.[doi:10.3969/j.issn.1672-3678.2012.05.010]
点击复制

重组人尿激酶原在CHO细胞中的高效表达及其纯化()
分享到:

《生物加工过程》[ISSN:1672-3678/CN:32-1706/Q]

卷:
10
期数:
2012年05期
页码:
50-54
栏目:
出版日期:
2012-09-30

文章信息/Info

Title:
Efficient expression of recombinant human pro-urokinase in CHO cells and its purification
文章编号:
1672-3678(2012)05-0050-05
作者:
李世崇叶玲玲刘红张正光高丽华胡显文陈昭烈
军事医学科学院 生物工程研究所,北京 100071
Author(s):
LI ShichongYE LinglingLIU HongZHANG ZhengguangGAO LihuaHU XianwenCHEN Zhaolie
Institute of Biotechnology, Academy of Military Medical Sciences, Beijing 100071, China
关键词:
CHO细胞 重组人尿激酶原 表达 纯化
分类号:
R392
DOI:
10.3969/j.issn.1672-3678.2012.05.010
文献标志码:
A
摘要:
用鸡β-globin的MAR序列和人看家基因延伸因子1α(hEF-1α)的调控序列以及旱獭RNA稳定与输出序列,构建了重组人尿激酶原(recombinant human pro-urokinase, rhPro-UK)的高效表达载体,在CHO细胞中获得了rhPro-UK的高效稳定表达,rhPro-UK的表达水平达到1 299 IU(以百万细胞1 d的表达量计)。采用阳离子交换层析、疏水层析和凝胶排阻层析的三步工艺纯化表达rhPro-UK的CHO细胞培养上清液,rhPro-UK的纯度达到98%、回收率为60%~70%。

参考文献/References:

[1] Kasai S,Arimura H,Nishida M,et al.Primary structure of single chain pro-urokinase[J].J Biol Chem,1985,260(22):12382-12389.
[2] Collen D,Zamarron C,Lijnen H R,et al.Activation of plasminogen by pro-urokinase[J].J Biol Chem,1986,262(3):1259-1266.
[3] Toombs C F.New directions in thrombolytic therapy [J].Curr Opin Pharmacol,2001,1(2):164-168.
[4] 宁荣霞,崔晓迎.新型溶栓药物重组人尿激酶原[J].中国新药杂志,2008,7(5):430-432.
[5] Wechesler L R.Intravenous thrombolytic therapy for acute ischemic stroke[J].New Eng J Med,2011,364:2138-2146.
[6] Nordt T K,Bode C.Thrombolysis:newer thrombolytic agents and their role in clinical medicine[J].Heart,2003,89:1358-1362.
[7] Stick T,Henry M T.Efficacy of thrombolytic agents in the treatment of pulmonary embolism[J].Eur Respir J,2005,26:864-874.
[8] Chen Z L,Wu B C,Liu H,et al.Temperature shift as a process optimization step for the production of pro-urokinase by a recombinant Chinese hamster ovary cell line in high-density perfusion culture[J].J Biosci Bioeng,2004,97(4):239-243.
[9] Jespersen J,Astrup T.A study of the fibrin plate assay of fibrinolytic agents:optimal conditions,reproducibility and precision [J].Hamostasis,1983,13(5):301-315.
[10] 萨姆布鲁克 J,弗里奇 E F,曼尼阿蒂斯 T,等.分子克隆实验指南[M].金冬雁,黎孟枫,林枫,等译.北京:科学出版社,1998:888-897.
[11] 李世崇,黄培堂,陈昭烈.CHO细胞表达新技术[J].生物技术通讯,2009,20(3):422-425.
[12] Barnes L M,Dickson A J.Mammalian cell factories for efficient and stable protein expression[J].Curr Opin Biotechnol,2006,17:381-386.
[13] Deer J R,Allison D S.High level expression of protein in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1ɑ gene[J].Biotechnol Prog,2004,20:880-889.
[14] Girod P A,Zahn-Zabal M,Mermod N.Use of chicken lysozyme 5’ matrix attachment region to generate high producer CHO cell lines [J] Biotechnol Bioeng,2005,91(1):1-11.
[15] Kim K S,Kim M S,Moon J H,et al.Enhancement of recombinant antibody production in HEK 293E cells by WPRE [J].Biotechnol Bioproc Eng,2009,14:633-638.
[16] Buko A M,Kentzer E J,Petros A,et al.Characterization of post-translation fucosylation in the growth factor domain of urinary type plasminogen activator[J].Proc Natl Acad Sci USA,1991,88:3992-3996.
[17] Sarubbi E,Nolli M L,Robbiati F,et al.The differential glycosylation of human pro-urokinase from various recombinant mammalian cell lines does not affect activity and binding to PAI-1[J].Thromb Haemost,1989,62(3):927-933.

备注/Memo

备注/Memo:
收稿日期:2012-04-11
基金项目:“重大新药创制”科技重大专项资助项目(2009ZX09503-011)
作者简介:李世崇(1968—),男,四川内江人,博士,研究方向:动物细胞工程; 陈昭烈(联系人),研究员,E-mail:chenzl23@sina.com.
更新日期/Last Update: 2012-09-30